News: Novo Nordisk A/S (NVO)

NVO on New York Consolidated

43.89USD
19 Dec 2014
Price Change (% chg)

$-0.51 (-1.15%)
Prev Close
$44.40
Open
$43.55
Day's High
$43.94
Day's Low
$43.46
Volume
1,844,574
Avg. Vol
1,502,155
52-wk High
$49.10
52-wk Low
$35.68

Search Stocks
Select another date:

Novo Nordisk gets positive opinion on Tresiba for children in Europe

COPENHAGEN - Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents.

Novo Nordisk gets positive opinion on Tresiba for children in Europe

COPENHAGEN, Dec 19 - Drug maker Novo Nordisk said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of its diabetes drug Tresiba for the treatment of children and adolescents.

BRIEF-Per Aarsleff to build shell structure for Novo Nordisk

* Has entered into a partnering contract with Novo Nordisk A/S to build a shell structure with a total gross area of 15,000 square metres

UPDATE 1-Bayer to seek approval for haemophilia drug this month

* Bay 81-8973 is based on Bayer's established Kogenate drug

NORDIC STOCKS - Factors to watch on Nov 25

OSLO, Nov 25 - The following stocks may be affected by newspaper reports and other factors on Tuesday:

BRIEF-Novo Nordisk has reduced the number of executives to six

COPENHAGEN, Nov 25 - Novo Nordisk A/S : ** Has reduced the number of executives from seven to six ** Executive vice president and chief of staffs Lise Kingo has decided to leave Novo Nordisk

BRIEF-Novo'S victoza receives positive opinion for use in adults with type 2 diabetes

COPENHAGEN, Nov 21 - Novo Nordisk A/S : ** Victoza receives positive Committee for Medicinal Products for Human Use opinion opinion for use in adults with type 2 diabetes and moderate renal impairment ** Once the European Commission approves the label expansion, physician s in the European Union will be able to prescribe Victoza, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments

BRIEF-Nine out of 10 lost weight with Novo's obesity drug -study

Nov 4 - Novo Nordisk A/S says: * New phase 3a data demonstrate that nine out of 10 adults with obesity lost

BRIEF-Novo Nordisk invests $130 mln in diabetes research in Denmark

* Invests 750 million Danish crowns in new laboratories for diabetes research in Denmark (around $130 million)

Novo Nordisk reassures on 2015 outlook after Sanofi jolt

COPENHAGEN - Novo Nordisk reassured investors that its diabetes drugs business in the United States would continue to grow, after French rival Sanofi warned that price competition would hamper its U.S. sales.

Select another date:
Search Stocks